Chris Porter,
Assistant Professor / Pediatrics,
University of Colorado School of Medicine
Dr. Porter is a pediatric hematologist-oncologist with extensive training in basic, translational and clinical research. His laboratory focuses on pediatric cancer, and primarily leukemia. They have optimized and used genome-wide and targeted shRNA libraries to identify novel therapeutic strategies for leukemia. For example, they screened the genome in acute myeloid leukemia (AML) cells to identify synthetic lethality with cytarabine, one of the most important conventional agents currently used to treat AML. They found that inhibition of the cell cycle checkpoint protein, Wee1, is synergistic with cytarabine in killing AML cells. He is collaborating with Medical Hematology-Oncologists to develop a clinical trial testing this strategy in humans with the first in class Wee1 inhibitor, AZ1775.
|
|
|
Add to Calendar ▼2014-09-23 10:30:002014-09-23 11:30:00Europe/LondonRNAi Screens to Identify Novel Therapeutic Strategies for Leukemia: Going All The WayAcademic Discovery Workshop in Baltimore, MD, USABaltimore, MD, USASELECTBIOenquiries@selectbiosciences.com
